| Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. | |
| | |
MedLine Citation:
|
PMID: 20684825 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. METHODS: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. RESULTS: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8+/-4.6 microg/mL at baseline to 10.3+/-6.9 microg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. CONCLUSION: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS. |
| | |
Authors:
|
Taiki Ohashi; Rei Shibata; Takeshi Morimoto; Masaaki Kanashiro; Hideki Ishii; Satoshi Ichimiya; Takafumi Hiro; Katsumi Miyauchi; Yoshihisa Nakagawa; Masakazu Yamagishi; Yukio Ozaki; Takeshi Kimura; Hiroyuki Daida; Toyoaki Murohara; Masunori Matsuzaki |
Related Documents
:
|
19556725 - Low incidence of cardiac events in statin-administered patients in cag study. 12542895 - Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with ang... 3608115 - Relation of parental history of early myocardial infarction to the level of apoprotein ... 2969235 - Lipoprotein lp(a). a risk factor for myocardial infarction. 18394025 - Nitric oxide depresses connexin 43 after myocardial infarction in mice. 9707265 - Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, a... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-05-11 |
Journal Detail:
|
Title: Atherosclerosis Volume: 212 ISSN: 1879-1484 ISO Abbreviation: Atherosclerosis Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-03 Completed Date: 2010-12-28 Revised Date: 2012-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland |
Other Details:
|
Languages: eng Pagination: 237-42 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Department of Cardiology, Yokkaichi Municipal Hospital, Yokkaichi, Japan. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00242944 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
blood,
drug therapy,
therapy*,
ultrasonography Adiponectin / blood Aged Angioplasty, Balloon, Coronary / adverse effects* Biological Markers / blood Cardiovascular Diseases / blood, etiology* Cholesterol, HDL / blood Coronary Vessels / drug effects*, ultrasonography Female Heptanoic Acids / therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Japan Logistic Models Male Middle Aged Odds Ratio Prospective Studies Pyrroles / therapeutic use* Quinolines / therapeutic use* Risk Assessment Risk Factors Time Factors Treatment Outcome Triglycerides / blood Ultrasonography, Interventional Up-Regulation |
| Chemical | |
Reg. No./Substance:
|
0/ADIPOQ protein, human; 0/Adiponectin; 0/Biological Markers; 0/Cholesterol, HDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/Quinolines; 0/Triglycerides; 110862-48-1/atorvastatin; 147511-69-1/pitavastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed b...
Next Document: Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion develo...